PDE7B and acute myeloid leukemia: The EFS time (P < 0.0001, Log-rank test, Fig. 3B) and OS time (P = 0.0021, Log-rank test, Fig. 3B) of AML patients who had received chemotherapy in the low expression level of PDE7B group were significantly longer than the high level PDE7B group.